Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.
Latest From Ayisha Sharma
Novartis’ Kisqali Could Challenge Pfizer’s Ibrance After Phase II First-Line Aggressive Breast Cancer Success
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a Phase II trial in first-line aggressive advanced breast cancer, supporting off-label use as the firm goes head to head with Pfizer’s rival drug Ibrance.
Janssen has dropped out of the running to acquire Irish biotech Horizon, leaving Sanofi and Amgen to vie over the potential megadeal, with some observers identifying the former as the better fit.
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
Recent executive changes in the industry include C-suite changes at AbbVie and Pharnext. Meanwhile, new directors were appointed at Zydus Lifesciences and FSD Pharma.